This company has been marked as potentially delisted and may not be actively trading. OTCMKTS:AVMXY AVITA MED LTD/S (AVMXY) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About AVITA MED LTD/S Stock (OTCMKTS:AVMXY) 30 days 90 days 365 days Advanced Chart Get AVITA MED LTD/S alerts:Sign Up Key Stats Today's Range$7.89▼$7.8950-Day Range$7.89▼$7.8952-Week Range$1.06▼$8.58VolumeN/AAverage Volume183,275 shsMarket Capitalization$651.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAvita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.Read More… Receive AVMXY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVITA MED LTD/S and its competitors with MarketBeat's FREE daily newsletter. Email Address AVMXY Stock News HeadlinesCantor maintains Avita stock Overweight with $19 targetFebruary 14, 2025 | msn.comAvita medical director Suzanne Crowe buys $6,390 in stockJanuary 30, 2025 | msn.comHow to target 627% gains from Trump’s tweetsPresident Trump is shaking up the market with his tweets and Truth Social posts... But while this chaos has scared investors and Wall Street over the past few months... One ex-Chicago Exchange trader is taking a very different approach to Trump’s 2nd term. In fact, he has an incredible 80%-win rate across all of his trades in 2025 so far.June 6, 2025 | Monument Traders Alliance (Ad)BTIG Reaffirms Their Hold Rating on Avita Medical (RCEL)January 13, 2025 | markets.businessinsider.comAvita Medical (RCEL) Gets a Buy from Lake StreetJanuary 9, 2025 | markets.businessinsider.comAvita Medical (RCEL) Receives a Hold from BTIGJanuary 7, 2025 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Avita Medical (RCEL)December 24, 2024 | markets.businessinsider.comAvita Medical Says FDA Approved Recell GO MiniDecember 23, 2024 | marketwatch.comSee More Headlines Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:AVMXY CIKN/A Webwww.avitamedical.com Phone661-367-9170FaxN/AEmployees55Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.50 Quick Ratio5.33 Sales & Book Value Annual Sales$5.51 million Price / Sales118.31 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book30.35Miscellaneous Outstanding Shares82,620,000Free FloatN/AMarket Cap$651.87 million OptionableNot Optionable Beta1.28 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTCMKTS:AVMXY) was last updated on 6/6/2025 by MarketBeat.com Staff From Our PartnersWhy hasn't Elon tweeted about this?Behind the scenes, there's an entirely different Tesla story brewing… . It's about a quiet stream of income...Investors Alley | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredU.S. Dollar Is Knocking on Death’s Door. 401(k)’s Next To GoRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHow to target 627% gains from Trump’s tweetsPresident Trump is shaking up the market with his tweets and Truth Social posts... But while this chaos has...Monument Traders Alliance | SponsoredThe Age of Chaos has begunThis is one of the most confusing markets in history. We have entered an Age of Chaos. And you must take...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVITA MED LTD/S Please log in to your account or sign up in order to add this asset to your watchlist. Share AVITA MED LTD/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.